A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children

Status: Active, no longer recruiting

Phase of Trial: Phase II/III

Latest Information Update: 16 Feb 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary)
Indications HIV-1 infections
Focus Adverse reactions; Pharmacokinetics; Registrational
Sponsors Gilead Sciences

Most Recent Events

10 Feb 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
10 Jun 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
22 Nov 2021 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight